AMPK-activation by Metformin in FSGS: AMP-FSGS

Summary

The primary objective of this study is to determine whether extended-release MF (in addition to standard of care (S-o-C)) is superior to placebo in reducing podocyte injury and promoting podocyte survival by 6-months in Focal Segmental Glomerulosclerosis (FSGS).

Timeline

Start

2023-12-14

Primary completion

2027-11

Completion

2027-11

Drugs

Indications